Anthem Biosciences Ltd

AI
Anthem Bioscienc Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Anthem Biosciences Ltd

₹ 942 2.93%
08 Nov - close price
anthembio.com BSE: 544449 NSE: ANTHEM
About

Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]

Key Points

Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.

Website BSE NSE
  • Market Cap ₹ 53,099 Cr.
  • Current Price ₹ 942
  • High / Low ₹ 978 / 579
  • Stock P/E 84.1
  • Book Value ₹ 58.2
  • Dividend Yield 0.21 %
  • ROCE 30.4 %
  • ROE 22.3 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company's working capital requirements have reduced from 118 days to 92.3 days

Cons

  • Stock is trading at 16.2 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology

Part of BSE Healthcare BSE 500 Nifty LargeMidcap 250 Nifty Midcap 150 Nifty MidSmallcap 400

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
339 525 498 483 540 550 423 611 418 594
218 330 338 288 349 332 266 344 268 323
Operating Profit 121 195 160 195 191 218 157 267 151 271
OPM % 36% 37% 32% 40% 35% 40% 37% 44% 36% 46%
19 28 24 14 23 48 8 52 25 59
Interest 4 4 3 1 2 3 0 2 1 3
Depreciation 19 20 20 30 26 34 35 40 30 31
Profit before tax 118 200 161 178 186 230 130 278 145 296
Tax % 30% 19% 23% 54% 27% 24% 29% 32% 17% 29%
82 162 124 83 136 173 93 190 120 211
EPS in Rs 1.47 2.90 2.22 1.48 2.42 3.09 1.65 3.38 2.13 3.75
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
633 1,103 1,231 1,057 1,419 1,845 2,124 2,046
451 695 666 626 914 1,173 1,290 1,200
Operating Profit 182 408 565 431 506 672 834 846
OPM % 29% 37% 46% 41% 36% 36% 39% 41%
21 37 49 139 63 85 131 144
Interest 20 17 10 9 10 11 7 6
Depreciation 62 62 58 64 82 89 134 135
Profit before tax 121 366 546 497 477 657 824 849
Tax % 23% 26% 26% 23% 23% 31% 28%
93 271 406 385 367 451 592 614
EPS in Rs 1.70 4.92 7.11 6.75 6.57 8.07 10.54 10.91
Dividend Payout % 0% 0% 0% 0% 0% 0% 19%
Compounded Sales Growth
10 Years: %
5 Years: 14%
3 Years: 26%
TTM: -1%
Compounded Profit Growth
10 Years: %
5 Years: 17%
3 Years: 21%
TTM: 22%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 35%
Return on Equity
10 Years: %
5 Years: 23%
3 Years: 21%
Last Year: 22%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 8 8 9 114 112 112 112 113
Reserves 413 693 1,346 1,627 1,813 2,298 2,930 3,168
159 100 35 126 239 113 54 40
207 232 228 148 235 284 333 365
Total Liabilities 787 1,034 1,619 2,014 2,398 2,808 3,429 3,686
306 361 329 449 483 705 783 768
CWIP 50 19 154 164 345 297 264 309
Investments 99 209 273 499 472 433 1,007 1,261
333 445 863 902 1,099 1,373 1,374 1,348
Total Assets 787 1,034 1,619 2,014 2,398 2,808 3,429 3,686

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
166 278 333 306 140 271 844
-109 -196 -205 -376 -221 -147 -702
-48 -63 181 64 -77 -136 -40
Net Cash Flow 9 18 308 -6 -158 -12 103
Free Cash Flow 119 159 307 112 -156 12 637
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 116% 85% 81% 98% 51% 64% 126%

Ratios

Consolidated / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 61 84 97 95 126 89 101
Inventory Days 186 29 52 139 129 167 56
Days Payable 87 50 50 77 61 54 34
Cash Conversion Cycle 160 63 99 156 193 202 124
Working Capital Days 20 27 75 112 128 134 92
ROCE % 55% 51% 28% 24% 28% 30%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Mar 2026
CRDMO Revenue Share
%

Log in to view insights

Please log in to see hidden values.

Login
Custom Synthesis Installed Capacity
kL
Fermentation Installed Capacity
kL
Number of Commercial Molecules
count
Number of Late-Phase (Phase 3) Molecules
count
Number of Scientific Staff
count
Custom Synthesis Capacity Utilization
%
Fermentation Capacity Utilization
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
74.69% 74.69% 74.67% 71.42% 71.39%
1.66% 1.37% 1.28% 2.57% 3.79%
7.21% 7.60% 11.55% 13.48% 12.10%
16.42% 16.34% 12.48% 12.52% 12.71%
No. of Shareholders 2,17,6811,99,4921,80,2201,73,2731,76,209

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls